Manufacturer of Controlled Substances; Notice of Application, 51400-51401 [2011-21120]
Download as PDF
<![CDATA[
51400
Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 19, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21068 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated May 13, 2011, and
published in the Federal Register on
May 27, 2011, 76 FR 30968, Almac
Clinical Services Inc., (ACSI), 25 Fretz
Road, Souderton, Pennsylvania 18964,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Almac Clinical Services Inc. (ACSI) to
import the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Almac Clinical Services Inc. (ACSI) to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: August 11, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21077 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By a Notice dated April 28, 2011, and
published in the Federal Register on
May 4, 2011 76 FR 25374, Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Raw Opium (9600) ..............................................................................................................................
Concentrate of Poppy Straw (9670) ....................................................................................................
The company plans to import the
listed controlled substances in order to
bulk manufacture controlled substances
in Active Pharmaceutical Ingredient
(API) form. The company distributes the
manufactured API’s in bulk form only to
its customers.
As explained in the Correction to
Notice of Application pertaining to
Rhodes Technologies, 72 FR 3417
(2007), comments and requests for
hearings on applications to import
narcotic raw material are not
appropriate.
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a), and
determined that the registration of
Rhodes Technologies to import the basic
classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
VerDate Mar<15>2010
16:04 Aug 17, 2011
Jkt 223001
protocols in effect on May 1, 1971. DEA
has investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
II
II
Dated: August 11, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21076 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 17, 2011,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
E:\FR\FM\18AUN1.SGM
18AUN1
51401
Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 17, 2011.
Dated: August 10, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 17, 2011.
Dated: August 10, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21118 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2011–21120 Filed 8–17–11; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Dated: August 10, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21074 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 27, 2011,
Austin Pharma LLC., 811 Paloma Drive,
Suite C, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 7, 2011,
Chemica, 316 West 130th Street, Los
Angeles, California 90061, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of Methamphetamine
(1105), a basic class of controlled
substance listed in schedule II.
The above listed controlled substance
is an intermediate in the manufacture of
Benzphetamine, a schedule III nonnarcotic controlled substance. The
methamphetamine will not be sold as a
commercial product. The company
plans to utilize a bulk active
pharmaceutical ingredient (API), as an
intermediate for the development of
another controlled substance, and
further distribution to its customers.
The methamphetamine will not be sold.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 13, 2011,
AMRI Rensselaer, Inc., 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Meperidine (9230) ........................
4-Anilino-N-Phenethyl-4-Piperidine (8333).
Fentanyl (9801) ............................
mstockstill on DSK4VPTVN1PROD with NOTICES
Springfield, Virginia 22152; and must be
filed no later than October 17, 2011.
I
I
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
VerDate Mar<15>2010
16:04 Aug 17, 2011
Jkt 223001
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
I
I
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 17, 2011.
Dated: August 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–21071 Filed 8–17–11; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 76, Number 160 (Thursday, August 18, 2011)]
[Notices]
[Pages 51400-51401]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-21120]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 17, 2011, Cambridge
Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made
application by renewal to the
[[Page 51401]]
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Morphine (9300), a basic class of controlled substance
listed in schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 17, 2011.
Dated: August 10, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-21120 Filed 8-17-11; 8:45 am]
BILLING CODE 4410-09-P
